Chapter 11. Paraneoplastic Syndromes
Ruthanne Chun
Paraneoplastic syndromes (PNS) are systemic disorders resulting from substances produced by a tumor. According to the strictest definition, PNS are caused by the production and release of substances not normally produced by the tumor cell of origin or in amounts not normally produced by those cells. Hypoglycemia resulting from an insulinoma, hyperglobulinemia resulting from multiple myeloma, and hyperestrogenism resulting from testicular tumors are mentioned in this chapter because of their effects on multiple systems in the body. Pathologies caused by PNS, as opposed to the finding of a tumor, may be the factor that prompts the client to pursue veterinary attention. Other etiologies of PNS aside from production of metabolically active substances include autoimmune disease induction, immune complex formation, immunosuppression, and ectopic receptor production/competitive blockade of normal hormones. PNS may also arise because of substances produced by normal cells caused by presence of the tumor (e.g., tumor necrosis factor production contributing to cancer cachexia). Many PNS in veterinary medicine are of unknown etiology.
PNS are common in human cancer patients. The PNS may precede identification of the cancer by weeks to years. Thus, recognition of PNS is important for many reasons. A PNS may be the first sign of disease, facilitating work-up and diagnosis. Monitoring the PNS can be an effective means of evaluating response to anti-cancer therapy and tumor relapse.
Clinically, PNS can cause greater morbidity and mortality than the primary tumor, thus greatly impacting patient quality and quantity of life. While resolution of the underlying tumor is the best way to eliminate the PNS, symptomatic therapies may control the PNS and improve quality of life. PNS, the tumors that cause them, clinical signs, and frequency are summarized in Table 11-1 .
CA , Carcinoma; HSA , hemangiosarcoma ; LSA , lymphoma; MM , multiple myeloma. | |||
Paraneoplastic Syndrome | Associated Tumor(s) | Systemic Effect | Frequency |
---|---|---|---|
Endocrinologic paraneoplastic syndromes | |||
Hypercalcemia | LSA, MM, thymoma, anal sac adenocarcinoma, parathyroid tumors, miscellaneous other | Polyuria/polydipsia, renal failure, arrhythmias, seizures, coma, death | Common |
Hypoglycemia | LSA, intestinal and hepatic tumors, insulinoma | Behavioral changes, seizures, death | Uncommon |
Hyperestrogenism | Testicular tumors | Alopecia, gynecomastia, skin changes, pancytopenia | Uncommon |
Hematologic paraneoplastic syndromes | |||
Anemia | LSA, MM, thymoma, HSA | Weakness, inappetence, or anorexia | Common |
Polycythemia | Renal and nasal tumors | Polydipsia, dark red mucous membranes, inappetence/anorexia, seizures, death | Rare |
Thrombocytopenia and coagulopathies | HSA, LSA, MM, multiple others | Petechiation, bleeding tendencies | Common |
Hyperglobulinemia | LSA, MM | Increased susceptibility to infection; hyperviscosity that is associated with heart failure, bleeding tendencies, renal failure, behavioral changes, seizures, polyuria | Uncommon |
Neutrophilic leukocytosis | Renal tumors, HSA | None | Rare |
Neurologic Paraneoplastic Syndromes | |||
Myasthenia gravis, peripheral neuropathy | LSA, thymoma, miscellaneous other | Regurgitation, weakness, depends upon affected site | Rare |
Cutaneous Paraneoplastic Syndromes | |||
Alopecia | Pancreatic or biliary CA, thymoma—cats | Easily epilated hair or alopecia | Rare |
Superficial necrolytic dermatitis | Glucagonoma or glucagon-secreting tumors, liver CA, pancreatic CA—cats | Alopecia, skin erosions and crusts, pad hyperkeratosis | Rare |
Miscellaneous Paraneoplastic Syndromes | |||
Hypertrophic osteopathy | Intrathoracic and intra-abdominal tumors | Lameness (often shifting leg lameness), limb edema | Uncommon |
Fever | Any | Lethargy, anorexia | Rare |
Cachexia | Any | Weight loss and anorexia | Rare |
ENDOCRINOLOGIC PARANEOPLASTIC SYNDROMES
Hypercalcemia
Hypercalcemia of malignancy is most commonly caused by production of parathyroid hormone-related peptide (PTH-rp) by tumor cells. 1-3 It is most often associated with lymphoma, anal sac adenocarcinoma, multiple myeloma, thymoma, and, especially in cats, squamous cell carcinoma; however, many other tumors have been linked with hypercalcemia. 4-14 Hypercalcemia may also be caused by primary hyperparathyroidism and excessive production of parathyroid hormone (PTH). 1,2 Although serum 1,25-dihydroxycholecalciferol (calcitriol) plays a role in hypercalcemia of malignancy in people, it does not appear to play a significant role in veterinary patients. 15-18 Other differentials for hypercalcemia are listed in Box 11-1 . 19-21
BOX 11-1
Laboratory error
Primary renal disease
Primary hyperparathyroidism
Hypervitaminosis D
Cholecalciferol rodenticides
Plant ingestion such as calcitrol glycosides
Iatrogenic
Hypervitaminosis A
Hemoconcentration
Hyperproteinemia
Skeletal lesions
Hypertrophic osteodystrophy
Osteomyelitis
Disuse osteoporosis
Factitious
Lipemia
Post-prandial samples
Young animal <6–12 mos
Thiazide diuretics
Granulomatous disease
Hypoadrenocorticism
Idiopathic hypercalcemia of cats
The most common clinical sign associated with this PNS is polyuria resulting from calcium interfering with renal tubule cell response to anti-diuretic hormone. Other signs may include polydipsia, inappetence, vomiting, weakness, bradycardia, obtundation, and death.
Because ionized calcium is the biologically active fraction, animals with elevated total calcium should be evaluated with measurement of ionized calcium. If the ionized calcium is high, serum should be submitted for PTH and PTH-rp measurement. It is important to note that not all animals with hypercalcemia of malignancy have persistently elevated serum calcium; values may fluctuate. If the PTH is normal or high in the face of hypercalcemia, primary hyperparathyroidism is likely. If the PTH-rp is normal or high in the face of hypercalcemia, malignancy is likely.
Therapy for hypercalcemia of malignancy is two-fold: treatment of the hypercalcemia if necessary and, more importantly, of the underlying malignancy. Animals with clinical signs of hypercalcemia beyond polyuria (e.g., weak, vomiting, bradycardic), typically those with total calcium ≥18 mg/dL, should be hospitalized and treated with aggressive fluid therapy using a calcium-replete solution (e.g., 0.9% NaCl at >66 ml/kg/day with urine output goal of 2 ml/kg/hr). Furosemide (2–4 mg/kg PO, SC, or IV bid) may be administered to promote calciuresis, provided the patient is well hydrated. Aside from serious clinical signs, other indications for treatment include a calcium phosphorus product (total calcium × phosphorus) ≥60. Other pharmacologic options for decreasing calcium include prednisone (1–2 mg/kg PO, SC, or IV bid), calcitonin (4-6 IU/kg SC bid to tid) or bisphosphonates. 22 The use of prednisone is ill-advised unless the patient has been screened for lymphoma, since steroid use may induce remission of this disease and can make subsequent diagnosis impossible. Calcitonin use may fall out of favor now that bisphosphonates are available and have been used in veterinary patients. Patients with unresolved hypercalcemia after saline-induced diuresis and furosemide should be treated with pamidronate at 1 mg/kg given over 2 hours in 250 ml 0.9% saline. 22,23 Effective treatment of the underlying malignancy is the approach most likely to resolve the hypercalcemia.
Hypoglycemia
< div class='tao-gold-member'>
Only gold members can continue reading. Log In or Register a > to continue